Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_018224.4(COA1):c.329G>A(p.Gly110Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000311 in 1,606,394 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
COA1 (HGNC:21868): (cytochrome c oxidase assembly factor 1) Involved in mitochondrial cytochrome c oxidase assembly and mitochondrial respiratory chain complex I assembly. Located in cytosol and mitochondrion. Is integral component of mitochondrial inner membrane. [provided by Alliance of Genome Resources, Apr 2022]
STK17A (HGNC:11395): (serine/threonine kinase 17a) This gene is a member of the DAP kinase-related apoptosis-inducing protein kinase family and encodes an autophosphorylated nuclear protein with a protein kinase domain. The protein has apoptosis-inducing activity. [provided by RefSeq, Jul 2008]
Uncertain significance, criteria provided, single submitter
clinical testing
Ambry Genetics
Aug 13, 2021
The c.329G>A (p.G110D) alteration is located in exon 5 (coding exon 4) of the COA1 gene. This alteration results from a G to A substitution at nucleotide position 329, causing the glycine (G) at amino acid position 110 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Loss of catalytic residue at G110 (P = 0.0245);Loss of catalytic residue at G110 (P = 0.0245);Loss of catalytic residue at G110 (P = 0.0245);Loss of catalytic residue at G110 (P = 0.0245);